JPMorgan Chase & Co’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.5M | Buy |
580,275
+139,473
| +32% | +$3.96M | ﹤0.01% | 1857 |
|
|
2025
Q1 | $13M | Sell |
440,802
-9,342
| -2% | -$276K | ﹤0.01% | 1994 |
|
|
2024
Q4 | $13.1M | Sell |
450,144
-16,941
| -4% | -$493K | ﹤0.01% | 2045 |
|
|
2024
Q3 | $21.5M | Sell |
467,085
-14,395
| -3% | -$661K | ﹤0.01% | 1661 |
|
|
2024
Q2 | $19.7M | Sell |
481,480
-411,994
| -46% | -$16.8M | ﹤0.01% | 1668 |
|
|
2024
Q1 | $22.8M | Sell |
893,474
-74,429
| -8% | -$1.9M | ﹤0.01% | 1603 |
|
|
2023
Q4 | $8.76M | Sell |
967,903
-2,799
| -0.3% | -$25.3K | ﹤0.01% | 2205 |
|
|
2023
Q3 | $6.19M | Buy |
970,702
+420,695
| +76% | +$2.68M | ﹤0.01% | 2298 |
|
|
2023
Q2 | $6.1M | Sell |
550,007
-2,977
| -0.5% | -$33K | ﹤0.01% | 2362 |
|
|
2023
Q1 | $8.49M | Buy |
552,984
+428,066
| +343% | +$6.57M | ﹤0.01% | 2110 |
|
|
2022
Q4 | $2.77M | Buy |
124,918
+13,797
| +12% | +$306K | ﹤0.01% | 2759 |
|
|
2022
Q3 | $1.81M | Sell |
111,121
-15,461
| -12% | -$252K | ﹤0.01% | 2988 |
|
|
2022
Q2 | $1.84M | Buy |
126,582
+25,467
| +25% | +$370K | ﹤0.01% | 3071 |
|
|
2022
Q1 | $1.87M | Sell |
101,115
-10,256
| -9% | -$189K | ﹤0.01% | 3229 |
|
|
2021
Q4 | $2.65M | Buy |
111,371
+84,266
| +311% | +$2M | ﹤0.01% | 3038 |
|
|
2021
Q3 | $668K | Buy |
27,105
+9,827
| +57% | +$242K | ﹤0.01% | 3816 |
|
|
2021
Q2 | $427K | Buy |
17,278
+2,139
| +14% | +$52.9K | ﹤0.01% | 4081 |
|
|
2021
Q1 | $330K | Buy |
15,139
+7,630
| +102% | +$166K | ﹤0.01% | 4250 |
|
|
2020
Q4 | $192K | Buy |
7,509
+1,274
| +20% | +$32.6K | ﹤0.01% | 4155 |
|
|
2020
Q3 | $180K | Buy |
+6,235
| New | +$180K | ﹤0.01% | 3783 |
|